

Ticket #: \_\_\_\_\_ Request Date: \_\_\_\_\_ Request Time: \_\_\_\_\_

## Procrit® Prior Authorization Request Form (Page 1 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>		Directions for Use:	
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>			

Clinical Information (required)	
<b>Select the diagnosis below:</b>	
<input type="checkbox"/> Anemia due to chronic kidney disease	
<input type="checkbox"/> Anemia in cancer patients on chemotherapy	
<input type="checkbox"/> Anemia in hepatitis C virus (HCV)-infected patients due to ribavirin in combination with interferon or peg-interferon	
<input type="checkbox"/> Anemia in HIV-infected patients	
<input type="checkbox"/> Anemia in patients with myelodysplastic syndrome (MDS)	
<input type="checkbox"/> Preoperative use for reduction of allogeneic blood transfusion in patients undergoing surgery	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

**For anemia due to chronic kidney disease, answer the following:**

Is the patient on dialysis?  Yes  No

Has the patient been evaluated for adequate iron stores?  Yes  No

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within **30 days** of this request:  
 Hemoglobin (Hgb): \_\_\_\_\_ Date: \_\_\_\_\_ Hematocrit (Hct): \_\_\_\_\_ Date: \_\_\_\_\_

Does the rate of hemoglobin decline indicate the likelihood of requiring a red blood cell (RBC) transfusion?  Yes  No

Is the goal of therapy to reduce the risk of alloimmunization and/or other RBC transfusion-related risks?  Yes  No

**Reauthorization:**

Has the patient been evaluated for adequate iron stores?  Yes  No

Is there a decrease in the need for blood transfusion with Procrit therapy?  Yes  No

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level?  Yes  No

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.  
 Office use only: Procrit\_Comm\_2017Dec

# Procrit® Prior Authorization Request Form (Page 2 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

## For anemia in cancer patients on chemotherapy, answer the following:

Have other causes of anemia been ruled out?  Yes  No

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within **the prior two weeks** of this request:

Hemoglobin (Hgb): \_\_\_\_\_ Date: \_\_\_\_\_ Hematocrit (Hct): \_\_\_\_\_ Date: \_\_\_\_\_

Has the patient been evaluated for adequate iron stores?  Yes  No

Is the cancer a non-myeloid malignancy?  Yes  No

Is the patient concurrently on chemotherapy?  Yes  No

Will the patient be receiving concomitant chemotherapy for a minimum of 2 months?  Yes  No

Is the anemia caused by cancer chemotherapy?  Yes  No

### Reauthorization:

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within **the prior two weeks** of this request:

Hemoglobin (Hgb): \_\_\_\_\_ Date: \_\_\_\_\_ Hematocrit (Hct): \_\_\_\_\_ Date: \_\_\_\_\_

Is there a decrease in the need for blood transfusion with Procrit therapy?  Yes  No

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level?  Yes  No

Is the patient concurrently on chemotherapy?  Yes  No

Will the patient be receiving concomitant chemotherapy for a minimum of 2 months?  Yes  No

Is the anemia caused by cancer chemotherapy?  Yes  No

## For anemia in HCV-infected patients due to ribavirin in combination with interferon or peg-interferon, answer the following:

Does the patient have a diagnosis of hepatitis C virus (HCV) infection?  Yes  No

Has the patient been evaluated for adequate iron stores?  Yes  No

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within **30 days** of this request:

Hemoglobin (Hgb): \_\_\_\_\_ Date: \_\_\_\_\_ Hematocrit (Hct): \_\_\_\_\_ Date: \_\_\_\_\_

Is the patient receiving ribavirin?  Yes  No

Is the patient receiving interferon alfa-2b, interferon alfacon-1, peginterferon alfa-2b, or peginterferon alfa-2a?  Yes  No

### Reauthorization:

Is there a decrease in the need for blood transfusion with Procrit therapy?  Yes  No

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level?  Yes  No

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

## For anemia in HIV-infected patients, answer the following:

Has the patient been evaluated for adequate iron stores?  Yes  No

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within **30 days** of this request:

Hemoglobin (Hgb): \_\_\_\_\_ Date: \_\_\_\_\_ Hematocrit (Hct): \_\_\_\_\_ Date: \_\_\_\_\_

Is the serum erythropoietin level less than or equal to 500 mU/mL?  Yes  No

Is the patient receiving zidovudine (AZT) therapy?  Yes  No

Does the patient have a diagnosis of HIV infection?  Yes  No

### Reauthorization:

Is there a decrease in the need for blood transfusion with Procrit therapy?  Yes  No

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level?  Yes  No

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Procrit\_Comm\_2017Dec

# Procrit® Prior Authorization Request Form (Page 3 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**For preoperative use for reduction of allogeneic blood transfusion in patients undergoing surgery, answer the following:**

Is the patient scheduled to undergo elective, non-cardiac, non-vascular surgery?  Yes  No

Is the hemoglobin (Hgb) > 10 to ≤ 13 g/dL?  Yes  No

Is the patient at high risk for perioperative transfusions?  Yes  No

Is the patient willing or able to donate autologous blood pre-operatively?  Yes  No

Has the patient been evaluated for adequate iron stores?  Yes  No

**For anemia in patients with myelodysplastic syndrome (MDS), answer the following:**

Is the serum erythropoietin level less than or equal to 500 mU/mL?  Yes  No

Does the patient have transfusion-dependent MDS?  Yes  No

Has the patient been evaluated for adequate iron stores?  Yes  No

**Reauthorization:**

Is there a decrease in the need for blood transfusion with Procrit therapy?  Yes  No

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level?  Yes  No

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

Hgb: \_\_\_\_\_ Hct: \_\_\_\_\_ Date: \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

Authorized Medical Signature:

Telephone:

Date:

**When Completed Return To:**

ProCare PBM Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507  
1-866-965-Drug (3784) / Fax # 866-999-7736

*Please note: This request may be denied unless all required information is received.*

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Procrit\_Comm\_2017Dec